Article Text

Download PDFPDF
A unique monoclonal antibody for therapeutic use against chronic hepatitis B: not all antibodies are created equal
  1. Camille Sureau
  1. Correspondence to Dr Camille Sureau, Laboratoire de Virologie Moléculaire, INSERM-U1134, INTS, 6 rue Alexandre-Cabanel, Paris 75739, France; csureau{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Even though current antiviral treatments based on pegylated interferon, or nucleos(t)ide analogues, in mono or combination therapies, have demonstrated clinical benefit to HBV-infected patients, chronic hepatitis B remains a difficult-to-cure disease. An absolute cure, defined as total elimination of HBV DNA, is currently not achievable, and a functional cure characterised by sustained virological response and HBV surface antigen (HBsAg) clearance off-treatment remains a challenge. Pegylated interferon treatment can lead to a sustained virological response and HBsAg clearance off-treatment in only 3–7% of patients,1 and it is too often associated with contraindications and adverse effects. Long-term treatment with nucleos(t)ide analogues is better tolerated, but the chance to achieve a sustained virological response and HBsAg loss remains low,2 and the drugs do not eradicate intrahepatic HBV DNA.

The risk of disease progression and development of hepatocellular carcinoma in chronically HBV-infected patients is clearly associated with high levels of serum HBV DNA and HBsAg.3 ,4 Since high levels of serum HBsAg may be responsible for exhaustion of HBsAg-specific T-cell response in chronically infected individuals, an antiviral strategy aimed at suppressing circulating HBsAg could restore virus-specific immune response and promote viral clearance.5

Zhang et al 6 investigated the potential of anti-HBsAg monoclonal antibodies (mAbs) infusion for clearance of circulating HBsAg in chronic infection. The study was based on (i) the previous observation that anti-HBsAg mAbs treatments could have short-term antiviral effects,7 ,8 and (ii) the growing interest in mAbs-based immunotherapy for viral diseases, including infections with HIV, HCV and Ebola virus.9 The therapeutic use of antiviral mAbs was initially based on the mAbs activity in virus neutralisation …

View Full Text


  • Competing interests CS is a CNRS scientist and he is supported by Agence Nationale pour la Recherche sur le SIDA et les hépatites virales (ANRS).

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles